PRIM vs REGN · P/E 22, rev $1.74B vs P/E 14, rev $14.34B
Primoris Services Corporation (PRIM) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Primoris Services Corporation (PRIM) is a engineering & construction company listed on NYSE.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported PRIM revenue for 2024-12-31 was $1.74B. Net income was $180.9M. Revenue was up 5.6% from 2024-09-30 to 2024-12-31. PRIM currently screens at market cap $5.52B and trailing P/E 22.4.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
PRIM currently screens at market cap $5.52B and trailing P/E 22.4. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the PRIM and REGN stock pages for the full models.
Not investment advice.